CalciMedica, Inc. (CALC)
| Market Cap | 120.98M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.61M |
| Shares Out | 1.53M |
| EPS (ttm) | -23.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 5.48 |
| Day's Range | 5.00 - 5.69 |
| 52-Week Range | 4.88 - 284.20 |
| Beta | 1.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 8, 2023 |
About CALC
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, a... [Read more]
Financial Performance
Financial StatementsNews
CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement
- CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC” - Cash and cash equivalents of approximately $34 million as of merger close expected...
Graybug Announces Name and Trading Symbol Change
REDWOOD CITY, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) today announced that it has changed its name to CalciMedica, Inc. (the Company), which will becom...
GRAYBUG VISION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graybug Vision, Inc. - GRAY
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Graybug Vision...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGO, GRAY, APEN, SAL
NEW YORK , Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...
INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of Graybug Vision, Inc. - GRAY
New York, New York--(Newsfile Corp. - December 5, 2022) - Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national s...
Shareholder Alert: Ademi LLP investigates whether Graybug Vision, Inc. has entered into a Fair Transaction with CalciMedica
MILWAUKEE , Nov. 22, 2022 /PRNewswire/ -- Ademi LLP is investigating Graybug (Nasdaq: GRAY) for possible breaches of fiduciary duty and other violations of law in its transaction with CalciMedica. Cl...
GRAY STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Graybug Vision, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Graybug Vision, Inc. (NASDAQ: GRAY) and CalciMedica Inc. is fair to Graybug sharehold...
Graybug and CalciMedica Enter into Definitive Merger Agreement
– Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica's pipeline of first-in-class product candidates for life-threatening inflammatory diseases
Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022
REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on developing ...
Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments
BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today p...
Graybug to Present at the 2022 OIS Retina Innovation Summit
BALTIMORE, July 06, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular ...
Graybug (GRAY) to Review Strategic Alternatives, Stock Up
Graybug's (GRAY) board of directors is set to review strategic options focused on maximizing shareholder value, including a potential sale of the company. Shares rise.
Graybug Vision (GRAY) Stock Soars 35% on Strategic Review News
Today, investors in Graybug Vision and GRAY stock are cheering an announced strategic review, which could see a sale of the company. The post Graybug Vision (GRAY) Stock Soars 35% on Strategic Review ...
Graybug Announces Review of Strategic Alternatives
BALTIMORE, June 28, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular ...
Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the Summit Meeting
BALTIMORE, May 19, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular d...
Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting
BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular...
Graybug to Present at the 2022 ASCRS Annual Meeting
BALTIMORE, April 18, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular...
Graybug Vision Appoints Dirk Sauer to Board of Directors
BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular...
Graybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023
BALTIMORE, March 30, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular...
Graybug Vision to Host Virtual R&D Day on March 30, 2022
BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular...
Graybug Vision Reports Full Year 2021 Financial Results and Recent Corporate Developments
Management to host R&D Day for investors on March 30, 2022 at 11 a.m. ET Management to host R&D Day for investors on March 30, 2022 at 11 a.m. ET
Graybug to Participate in Three Upcoming Medical and Investor Conferences
BALTIMORE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of disease...
Graybug Vision Makes Key Hires to Further Build Momentum Behind its Pipeline
BALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of disease...
Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corporate Developments
BALTIMORE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of disease...
Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting
BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of disease...